Abstract: The present invention provides a prophylactic or therapeutic agent, a pharmaceutical composition and a health-promoting food, which are used for human or other animal for the inhibition of the onset or progress of liver cancer, namely, an inhibitor of the onset or progress of liver cancer, which contains isoleucine, leucine and valine as active ingredients, wherein the weight ratio of isoleucine, leucine and valine is preferably 1:1.5 to 2.5:0.8 to 1.7 and the daily dose is 2.0 g to 50.0 g.

Abstract: The present invention provides a prophylactic or therapeutic agent, a pharmaceutical composition and a health-promoting food, which are used for human or other animal for the inhibition of the onset or progress of liver cancer, namely, an inhibitor of the onset or progress of liver cancer, which contains isoleucine, leucine and valine as active ingredients, wherein the weight ratio of isoleucine, leucine and valine is preferably 1:1.5 to 2.5:0.8 to 1.7 and the daily dose is 2.0 g to 50.0 g.

Abstract: A treatment method more effective in treating tumors such as cancer by administering activated lymphocytes in combination with a photodynamic therapy procedure within a specific period of time preceding or following the procedure is provided. By treating the patient with the combination of PDT procedure and the activated lymphocyte administration, a remarkable effect is achieved in reducing and suppressing various types of tumors, including stomach cancer in particular, and also desirable results are achieved even when tumors not responsive to PDT procedure alone are treated in this manner, due to the synergy of the PDT procedure and the activated lymphocyte administration. Provided that the activated lymphocytes are used in combination with a PDT procedure, even activated lymphocytes not necessarily achieving cancer specificity can be expected to improve the treatment effect in destroying or suppressing the growth of tumors such as cancers.